MET and renal cell carcinoma: The PET tracer [68Ga]-EMP-100, a novel PET ligand based on a c-Met-binding peptide, was used to visualize c-MET expression in metastatic RCC and showed high uptake in primary tumors and metastases in the first human study (n = 12) [20].